Your browser is no longer supported. Please, upgrade your browser.
Settings
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Index- P/E449.60 EPS (ttm)0.10 Insider Own4.50% Shs Outstand101.65M Perf Week0.70%
Market Cap4.53B Forward P/E- EPS next Y-0.97 Insider Trans-5.22% Shs Float99.05M Perf Month27.14%
Income9.50M PEG61.34 EPS next Q-0.11 Inst Own65.50% Short Float8.48% Perf Quarter31.41%
Sales139.00M P/S32.56 EPS this Y205.90% Inst Trans1.30% Short Ratio6.88 Perf Half Y-24.48%
Book/sh4.86 P/B9.16 EPS next Y-90.20% ROA2.10% Target Price62.10 Perf Year69.30%
Cash/sh3.03 P/C14.71 EPS next 5Y7.33% ROE2.60% 52W Range19.51 - 73.72 Perf YTD-29.83%
Dividend- P/FCF- EPS past 5Y20.60% ROI24.90% 52W High-39.62% Beta1.83
Dividend %- Quick Ratio5.90 Sales past 5Y295.20% Gross Margin- 52W Low128.14% ATR2.14
Employees134 Current Ratio5.90 Sales Q/Q-51.10% Oper. Margin0.80% RSI (14)65.85 Volatility3.95% 6.18%
OptionableYes Debt/Eq0.00 EPS Q/Q-180.10% Profit Margin6.90% Rel Volume0.59 Prev Close45.15
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout0.00% Avg Volume1.22M Price44.51
Recom2.00 SMA2011.05% SMA5020.81% SMA2007.19% Volume722,368 Change-1.42%
May-13-20Initiated RBC Capital Mkts Outperform $62
May-08-20Upgrade Oppenheimer Perform → Outperform $58
Apr-15-20Upgrade Cantor Fitzgerald Neutral → Overweight $55 → $60
Mar-24-20Upgrade SVB Leerink Underperform → Mkt Perform $29
Mar-17-20Initiated Goldman Neutral $45
Jan-21-20Initiated SVB Leerink Underperform $32
Dec-13-19Initiated Oppenheimer Perform
Nov-29-19Reiterated Chardan Capital Markets Buy $45 → $81
Nov-27-19Reiterated B. Riley FBR Buy $59 → $83
Nov-25-19Upgrade Robert W. Baird Neutral → Outperform $70
Oct-24-19Downgrade Robert W. Baird Outperform → Neutral $39
Oct-22-19Reiterated Chardan Capital Markets Buy $32 → $45
Oct-03-19Initiated Robert W. Baird Outperform $39
Sep-07-18Upgrade B. Riley FBR Neutral → Buy $18 → $19
Sep-06-18Reiterated Chardan Capital Markets Buy $17.50 → $24.50
Aug-08-18Reiterated Cantor Fitzgerald Overweight $13 → $18
Jul-02-18Reiterated Chardan Capital Markets Buy $9.50 → $16
May-09-18Upgrade Cantor Fitzgerald Neutral → Overweight $13
Mar-27-18Initiated Jefferies Buy $10
Feb-12-18Reiterated Cantor Fitzgerald Neutral $2 → $5
Jul-09-20 08:19AM  
07:30AM  
Jul-08-20 04:00PM  
10:13AM  
Jun-16-20 09:46PM  
09:30AM  
Jun-02-20 12:35PM  
May-30-20 06:35PM  
May-28-20 07:30AM  
May-24-20 10:10AM  
May-22-20 11:34AM  
May-19-20 07:02AM  
May-10-20 08:20AM  
May-08-20 09:30PM  
May-07-20 04:00PM  
May-01-20 04:00PM  
04:00PM  
Apr-30-20 07:52AM  
Apr-22-20 07:30AM  
Apr-20-20 06:31AM  
Apr-10-20 07:30AM  
Apr-06-20 06:26PM  
10:30AM  
Mar-20-20 02:15PM  
Mar-18-20 08:00PM  
Mar-17-20 04:10PM  
04:10PM  
Mar-15-20 08:30AM  
Mar-10-20 04:16PM  
Mar-03-20 07:30AM  
Mar-02-20 04:00PM  
Feb-13-20 04:47PM  
Feb-12-20 09:37PM  
Feb-07-20 09:36AM  
Feb-06-20 07:47AM  
Feb-05-20 04:00PM  
04:00PM  
07:43AM  
Feb-03-20 01:06PM  
Jan-24-20 05:31AM  
Jan-22-20 04:29PM  
07:30AM  
Jan-21-20 04:30PM  
Jan-16-20 03:55PM  
Jan-11-20 08:00AM  
Jan-10-20 11:51AM  
Jan-06-20 07:30AM  
Jan-02-20 08:00AM  
Dec-27-19 06:06PM  
Dec-26-19 05:27AM  
Dec-24-19 10:00AM  
Dec-23-19 10:21AM  
08:00AM  
Dec-20-19 07:30AM  
Dec-16-19 10:55PM  
04:15PM  
07:30AM  
Dec-13-19 06:12PM  
07:30AM  
Dec-11-19 03:46PM  
07:30AM  
Dec-06-19 04:01PM  
Dec-04-19 06:00AM  
Dec-03-19 09:26AM  
06:55AM  
Dec-02-19 04:48PM  
04:05PM  
02:57PM  
Nov-29-19 01:23PM  
09:52AM  
Nov-28-19 08:07AM  
Nov-27-19 07:26AM  
04:55AM  
Nov-26-19 04:00PM  
Nov-25-19 04:00PM  
10:27AM  
Nov-18-19 09:32AM  
Nov-15-19 07:30AM  
Nov-13-19 02:12PM  
Nov-11-19 07:30AM  
06:29AM  
Nov-08-19 04:13PM  
08:00AM  
Nov-06-19 06:38AM  
Oct-31-19 12:15PM  
06:30AM  
Oct-30-19 08:41AM  
Oct-26-19 07:51AM  
Oct-23-19 01:25PM  
Oct-18-19 04:38PM  
11:10AM  
07:30AM  
Oct-04-19 12:11PM  
Oct-02-19 04:15PM  
Sep-30-19 04:00PM  
Sep-27-19 09:15AM  
Sep-20-19 04:00PM  
10:19AM  
Sep-16-19 03:00AM  
Sep-09-19 06:51AM  
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD for treating liver diseases; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anzalone Christopher RichardChief Executive OfficerJun 25Sale38.81100,0003,881,0172,605,237Jun 26 06:02 PM
De Backer MarianneDirectorJun 15Buy31.3350015,66516,500Jun 24 06:10 PM
PERRY MICHAEL SDirectorMay 14Option Exercise3.7077,000285,20085,000May 18 06:27 PM
PERRY MICHAEL SDirectorMay 12Sale35.8336,0001,289,8918,000May 13 06:48 PM
Waddill William D.DirectorMay 11Sale36.5426,000950,04028,000May 13 06:45 PM
GIVEN BRUCE DChief Operating OfficerApr 28Option Exercise8.614,19736,131855,831Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 28Sale40.005,101204,040850,730Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 27Option Exercise5.192001,038851,934Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 27Sale40.0030012,000851,634Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 20Option Exercise8.1416,256132,286875,249Apr 22 07:00 PM
GIVEN BRUCE DChief Operating OfficerApr 20Sale40.0023,515940,600851,734Apr 22 07:00 PM
De Backer MarianneDirectorApr 15Buy35.4050017,70016,000Jun 24 06:10 PM
GIVEN DOUGLAS BDirectorApr 14Sale36.8925,000922,250155,925Apr 16 07:47 PM
De Backer MarianneDirectorMar 16Buy23.9450011,97015,500Jun 24 06:10 PM
De Backer MarianneDirectorMar 12Buy24.8050012,40015,000Jun 24 06:10 PM
De Backer MarianneDirectorMar 11Buy28.6050014,30014,500Jun 24 06:10 PM
De Backer MarianneDirectorFeb 28Buy34.3950017,19514,000Jun 24 06:10 PM
De Backer MarianneDirectorFeb 27Buy35.0750017,53513,500Jun 24 06:10 PM
Myszkowski Kenneth AllenChief Financial OfficerFeb 25Option Exercise8.8443,445384,145427,668Feb 27 05:41 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 21Option Exercise5.1933,351173,092424,536Jan 23 06:15 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 21Sale49.4440,3131,992,925384,223Jan 23 06:15 PM
De Backer MarianneDirectorJan 13Buy54.9550027,47513,000Jun 24 06:10 PM
GIVEN BRUCE DChief Operating OfficerJan 06Sale60.1335,6132,141,285858,993Jan 08 06:35 PM
O'Brien PatrickGeneral CounselJan 06Sale60.1214,625879,261258,375Jan 08 06:33 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 06Sale60.1120,0001,202,201391,185Jan 08 06:31 PM
Anzalone Christopher RichardChief Executive OfficerDec 24Sale63.5083,3335,291,6461,805,237Dec 27 04:54 PM
Anzalone Christopher RichardChief Executive OfficerDec 13Sale66.7383,3335,560,4891,888,570Dec 13 06:35 PM
Anzalone Christopher RichardChief Executive OfficerDec 12Sale67.50100,0006,749,6301,971,903Dec 13 06:35 PM
Anzalone Christopher RichardChief Executive OfficerDec 03Sale61.5812,033740,9522,071,903Dec 04 06:48 PM
Anzalone Christopher RichardChief Executive OfficerDec 02Sale69.1537,9672,625,5702,083,936Dec 04 06:48 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 05Option Exercise5.1912,64965,648326,185Nov 07 06:45 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 01Option Exercise7.7537,884293,601351,420Nov 01 07:32 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 01Sale40.8537,8841,547,378313,536Nov 01 07:32 PM
Anzalone Christopher RichardChief Executive OfficerOct 10Option Exercise5.2056,325292,8902,178,228Oct 11 07:31 PM
Anzalone Christopher RichardChief Executive OfficerOct 10Sale31.8356,3251,792,8252,121,903Oct 11 07:31 PM
Anzalone Christopher RichardChief Executive OfficerSep 25Sale28.2520,000565,0002,121,903Sep 27 09:16 PM
Anzalone Christopher RichardChief Executive OfficerSep 24Option Exercise5.1066,645339,8902,208,548Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 24Sale28.2066,6451,879,2402,141,903Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 23Option Exercise5.1041,755212,9512,183,658Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 23Sale29.0441,7551,212,5652,141,903Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 20Option Exercise5.104,25021,6752,146,153Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 20Sale29.004,250123,2502,141,903Sep 24 09:12 PM
PERRY MICHAEL SDirectorSep 11Sale30.0085,0002,550,00036,000Sep 11 08:09 PM
PERRY MICHAEL SDirectorSep 09Sale28.90100,0002,890,000121,000Sep 11 08:09 PM